Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Geodon CV Safety Trial Fully Enrolled; Rx Growth Slows

Executive Summary

Pfizer has completed enrollment in a cardiovascular safety study of the antipsychotic Geodon (ziprasidone), the company told investors during an Oct. 17 conference call.

You may also be interested in...



Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk

Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)

Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk

Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)

Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

Related Content

UsernamePublicRestriction

Register

PS038751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel